BOSTON — AcuityMD announced it has secured $80 million in new funding to enhance its artificial intelligence platform and support broader adoption of medical technology across the MedTech industry.
The Series C funding round was led by existing investor StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. The company said it has now raised more than $160 million to date and is valued at $955 million.
The funding will be used to advance AcuityMD’s AI capabilities, deepen its proprietary data model, and expand the platform beyond commercial applications. The company currently works with 16 of the top 20 MedTech companies and said its platform has helped customers identify more than $34 billion in pipeline opportunities.
“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” said Hunter Somerville, partner at StepStone Group. “The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”
AcuityMD said its platform was designed to address fragmented data challenges in the MedTech sector, where critical commercial insights are often spread across claims databases, regulatory filings, government records, and other sources. The company aggregates this information into a unified data model that maps relationships between physicians, healthcare facilities, procedures, and reimbursement dynamics, while integrating customer-specific data such as contracts and sales activity.
The company has also introduced AcuityAI, now in open beta, which builds on this data foundation to provide real-time insights tailored to individual users. The tool is designed to help sales teams identify opportunities more efficiently and engage with healthcare providers using more targeted information.
“AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”
The new capital will support development of AI tools for sales, marketing, and leadership teams, as well as further expansion of the company’s data infrastructure. AcuityMD said it also plans to extend its platform beyond commercial use cases as part of a broader effort to accelerate adoption of medical technologies throughout the product lifecycle.
“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I’m grateful to the hundreds of customers who have helped shape our platform,” said Mike Monovoukas, CEO and co-founder of AcuityMD. “This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”
